Overview
What is Proteogenomics Research Institute For Systems Medicine?
Proteogenomics Research Institute for Systems Medicine (PRISM) is a distinguished nonprofit research organization situated in San Diego, California. With a mission to innovate, PRISM focuses on combating a wide array of human diseases, particularly cancer. Utilizing the principles of systems science, an interdisciplinary approach, PRISM studies the intricate relationships between healthy and diseased tissues. Their cutting-edge facilities integrate advanced technologies in proteomics, genomics, and in vivo imaging to discover and validate novel therapeutic targets. By developing novel molecules and probes, PRISM enables dynamic, non-invasive functional imaging of both healthy and diseased tissues in vivo. These innovative tools form the foundation for new therapies designed to target only affected organs, minimizing harm to normal tissues and cells. This strategic approach promises more effective, less toxic treatments for individuals battling chronic and life-threatening illnesses. With a team of 40 dedicated professionals, PRISM continues to pioneer breakthroughs in biomedical research.
Official website here: www.prism-sd.org
Is Proteogenomics Research Institute For Systems Medicine legitimate?
Proteogenomics Research Institute For Systems Medicine is a legitimate nonprofit organization registered as a 501(c)(3) entity. Proteogenomics Research Institute For Systems Medicine submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $330,861
Professional Fundraising Fees: $0
Other Salaries and Wages: $2,068,083
For more financial information, click here
Official website here: www.prism-sd.org
What is the mission statement of Proteogenomics Research Institute For Systems Medicine?
The Proteogenomics Research Institute for Systems Medicine (PRISM) is a non-profit biomedical research institution dedicated to advancing innovative treatments for various human diseases, primarily focusing on cancer. Utilizing the principles of systems science, PRISM employs a comprehensive approach to study the intricate relationships between healthy and diseased tissues. Equipped with state-of-the-art facilities, PRISM combines advanced technologies in proteomics, genomics, and in vivo imaging to identify and validate novel therapeutic targets. By developing novel molecules and probes, PRISM aims to create dynamic, non-invasive functional imaging tools for both healthy and diseased tissues in vivo. These tools form the foundation for new therapies that can specifically target diseased organs while preserving normal tissues and cells, ultimately leading to more effective, less toxic treatments for patients suffering from chronic and life-threatening diseases.
Official website here: www.prism-sd.org
Who is the CEO of Proteogenomics Research Institute For Systems Medicine?
Jan E Schnitzer Md is the President & Ceo of Proteogenomics Research Institute For Systems Medicine. The CEO's salary of Proteogenomics Research Institute For Systems Medicine is $200,973 and their total compensation is $274,870.
Official website here: www.prism-sd.org
What is the revenue of Proteogenomics Research Institute For Systems Medicine?
Proteogenomics Research Institute For Systems Medicine's revenue in 2022 was $6,513,962.
Official website here: www.prism-sd.org
Who are the executives of Proteogenomics Research Institute For Systems Medicine and what are their salaries?
The average compensation at Proteogenomics Research Institute For Systems Medicine during 2022 was $59,974. There are 40 employees at Proteogenomics Research Institute For Systems Medicine.
Here are 8 key members and their salaries (Proteogenomics Research Institute For Systems Medicine's CEO's salary is $200,973 and their total compensation is $274,870):
- Jan E Schnitzer Md (President & Ceo)
- Michael Levin (Dir Nanotechnology)
- Bogdan Olenyuk (Professor)
- Timothy Buss (Sr Research Scient)
- Adrian Chrastina (Asst. Professor)
- L Jean Remmer (Vice President)
- John Roussin (Director)
- Eve Dreyfus Md (Director)
Official website here: www.prism-sd.org
Where can I find the form 990 for Proteogenomics Research Institute For Systems Medicine?
The Proteogenomics Research Institute For Systems Medicine’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.prism-sd.org
Learn more at the official website: www.prism-sd.org
Mission Statement of Proteogenomics Research Institute For Systems Medicine
Proteogenomics Research Institute for Systems Medicine, often referred to as PRISM, is a dedicated non-profit biomedical research organization. Its primary mission revolves around the innovative development of treatments for a broad array of human diseases, with a significant focus on cancer. PRISM employs the principles of systems science, an interdisciplinary approach that seeks to understand the intricate relationships between healthy and diseased tissues.
At the heart of PRISM's operations are its advanced facilities, which integrate cutting-edge technologies in proteomics, genomics, and in vivo imaging. These resources enable PRISM researchers to discover and validate novel therapeutic targets. By developing innovative molecules and probes, PRISM strives to create dynamic, non-invasive functional imaging tools that can specifically identify and target diseased organs, while sparing normal tissues and cells. This approach not only promises more effective treatments but also reduces toxicity, potentially extending the lives of patients diagnosed with chronic and life-threatening diseases and improving their overall quality of life.
Impact
This information is meant to be a general summary of Proteogenomics Research Institute For Systems Medicine. Please take the time to review official sources before making any decisions based upon the content provided here.
Saturday, July 20, 2024
Proteogenomics Research Institute For Systems Medicine (PRISM) has made a significant impact in the field of biomedical research by developing innovative treatments for a wide range of human diseases, with a primary focus on cancer. Through the application of systems science principles and cutting-edge technologies in proteomics, genomics, and in vivo imaging, PRISM has been able to identify and validate novel therapeutic targets that are crucial for the development of more effective and less toxic treatments.
By developing novel molecules and probes that allow for dynamic and non-invasive functional imaging of healthy and diseased tissues in vivo, PRISM is at the forefront of creating therapies that specifically target diseased organs while sparing normal tissues and cells. This approach not only extends the lives of patients diagnosed with chronic and life-threatening diseases but also improves their quality of life by reducing the toxic effects of traditional treatments.
Overall, PRISM's work has the potential to revolutionize the way diseases are diagnosed and treated, offering new hope to patients and paving the way for more personalized and targeted therapies in the future.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
PROGRAM REVENUE
Revenue
$10,389
Organization Details
Founding Year
2009
Phone
(858) 450-9999
Principal Officer
Jan E Schnitzer Md
Main Address
PO BOX 910212, SAN DIEGO, CA, 92191
Website
www.prism-sd.org
NTEE Category
Code: G053 - Disease
If you are a representative of Proteogenomics Research Institute For Systems Medicine and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.